Clinical Trial Detail

NCT ID NCT01664910
Title CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

hematologic cancer

Therapies

Bendamustine + Fludarabine + Inotuzumab ozogamicin

Rituximab

anti-thymocyte globulin

Tacrolimus

Age Groups: adult senior

No variant requirements are available.